Sight Sciences (SGHT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting opened virtually with introductions of board members, officers, independent auditor, and outside counsel.
Agenda and rules of conduct were made available on the virtual meeting webpage.
Voting procedures and eligibility were explained, with polls open for all proposals.
Board and executive committee updates
Board members and executive officers in attendance were introduced, including the Board Chair, CTO, COO, CFO, CLO, and EVP of Operations.
Shareholder proposals
Two proposals were presented: re-election of two Class II directors and ratification of the independent auditor.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sight Sciences
- Interventional glaucoma and dry eye platforms drive growth, clinical impact, and market expansion.SGHT
Investor presentation - Q2 2026 revenue up 20% YoY, gross margin 91%, net loss narrowed, and guidance raised.SGHT
Q2 2026 - Omni and TearCare outperform amid regulatory shifts, with major growth expected as coverage expands.SGHT
Stifel 2025 Virtual Ophthalmology Forum - OMNI and TearCare drive growth with innovation, higher utilization, and expanding market access.SGHT
Stifel 2026 Virtual Ophthalmology Forum - Interventional glaucoma and dry eye businesses are accelerating growth with strong clinical and payer momentum.SGHT
Bank of America Global Healthcare Conference 2026 - Driving growth with innovative interventional eyecare technologies and strong clinical outcomes.SGHT
Investor presentation - Q1 2026 revenue up 13%, net loss narrowed, and $55.4M litigation award granted.SGHT
Q1 2026 - Q4 revenue grew 7% with strong margins; 2026 guidance projects up to 14% growth.SGHT
Q4 2025 - Q1 2025 revenue fell 9% to $17.5M; guidance reaffirmed despite tariff and policy headwinds.SGHT
Q1 2025